Romiplostim for Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany

CONCLUSION: Romiplostim was effective and well tolerated in patients with newly diagnosed, persistent, or chronic ITP in routine clinical practice.PMID:34959233 | DOI:10.1159/000521689

Source: Acta Haematologica - December 27, 2021 Category: Hematology Authors: Marcel Reiser Klaus M Josten Hermann Dietzfelbinger Anouchka Seesaghur Markus Schill Jane Hippenmeyer Manfred Welslau Source Type: research